Navigation Links
Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Association's 71st Annual Scientific Sessions
Date:6/24/2011

6 kg/m2 and mean A1C 8.0 percent.

Key Findings:

  • Lixisenatide once daily achieved its primary endpoint of  non-inferiority in A1C reduction versus exenatide twice daily (LS mean +/- SE change from baseline: -0.79 +/- 0.05 vs. -0.96 +/- 0.05)
  • Improvements in mean fasting plasma glucose – measurement of blood glucose levels when a patient is fasting – (LS mean +/- SE change from baseline: -22.0 +/- 2.1 vs. -26.1 +/- 2.1) and the percentage of patients achieving the study target A1C < 7.0 percent (48.5% vs. 49.8%) were comparable between groups
  • Mean body weight significantly decreased from baseline in the lixisenatide group compared to the exenatide group (94.5 to 91.7 kg with lixisenatide vs. 96.7 to 92.9 kg with exenatide)
  • The proportion of patients with serious adverse events was generally comparable between groups
  • Discontinuations due to adverse events (mainly gastrointestinal events including nausea, diarrhea and vomiting) were 33 (10.4%) in the lixisenatide group and 41 (13.0%) in the exenatide group
  • Significantly fewer patients experienced symptomatic hypoglycemia with lixisenatide (2.5% vs. 7.9%, p<0.05), with 6-fold fewer hypoglycemic events (8 vs. 48) versus exenatide
  • More lixisenatide patients tolerated the target dose of 20 microgram per day and completed the trial versus the exenatide 10 mcg target dose (93% vs. 83%)

  • "Lixisenatide  Significantly  Improves  Glycemic  Control  in  Asian  Patients   with  Type  2 Diabetes Insufficiently Controlled on Basal Insulin +/- Sulfonylurea" [ABSTRACT 0278-OR]Data from the GetGoal-L Asia trial, showed in  Asian patients with type 2 diabetes insufficiently controlled by basal insulin +/- sulfonylurea, that lixisenatide once daily significantly improved glycemic control (as  measured by the number of patients reaching  a target A1C < 6.5 percent or
    '/>"/>

    SOURCE Euro RSCG Life
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
    3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
    5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
    7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
    8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
    9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
    10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
    11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2015)... July 28, 2015  Roche (SIX: RO, ROG; ... Association for Clinical Chemistry (AACC) 2015 Clinical Lab ... platforms and a unique educational initiative that demonstrates ... the value of the laboratory. The ... to empower laboratories and the people within them ...
    (Date:7/28/2015)... DUBLIN , July 20, 2015 ... announced the addition of the "Global Post-traumatic Stress ... The global PTSD therapeutics market to grow ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
    (Date:7/27/2015)... N.Y. and PARIS , ... REGN)  and Sanofi have entered into a new ... cancer treatments in the emerging field of immuno-oncology. As ... develop a programmed cell death protein 1 (PD-1) inhibitor ... clinical trials in 2016 with new therapeutic candidates based ...
    Breaking Medicine Technology:Roche introduces LabLeaders educational initiative to help redefine the value of the laboratory at AACC 2015 Clinical Lab Expo 2Roche introduces LabLeaders educational initiative to help redefine the value of the laboratory at AACC 2015 Clinical Lab Expo 3Roche introduces LabLeaders educational initiative to help redefine the value of the laboratory at AACC 2015 Clinical Lab Expo 4Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019 - Growing Number of Accidents and Violence Worldwide Drives the Market 2Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 2Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 3Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 4Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 5Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 6Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 7Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 8
    ... July 21 Amicus Therapeutics (Nasdaq: FOLD ... John F. Crowley , testified on behalf of the Biotechnology ... Labor and Pensions bipartisan, full committee hearing focused on rare ... on Capitol Hill. Mr. Crowley, a member of the Board ...
    ... Understanding and managing asthma is not always easy, especially without ... mother of two children with asthma, Dayanara Torres , ... (AAFA) and Merck to launch the Asma En Espanol initiative, ... learn more about asthma triggers and ways to manage the ...
    Cached Medicine Technology:Amicus CEO Represents BIO on Rare Diseases at U.S. Senate Committee on Health, Education, Labor and Pensions Bipartisan Hearing 2Amicus CEO Represents BIO on Rare Diseases at U.S. Senate Committee on Health, Education, Labor and Pensions Bipartisan Hearing 3Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 2Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 3Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 4Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 5Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 6
    (Date:7/28/2015)... ... July 28, 2015 , ... ... Invisible Aligner System to its online product offerings, giving its customers the ... model and cloud-based technology, SmileCareClub allows patients to get quality, remote invisible aligner ...
    (Date:7/28/2015)... ... ... Women fear developing Alzheimer's disease more than having a heart attack or ... treatable, but there is little an individual can do to arrest the progress of ... trial, reports the July 2015 Harvard Women's Health Watch . , "There are ...
    (Date:7/28/2015)... ... 2015 , ... The PULs Cardiac Test™ identifies asymptomatic patients ... of whom are missed by conventional evaluation , A currently unmet need ... disease, who are at risk of experiencing a coronary event, and for whom ...
    (Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... trusted source for identifying Top Doctors, has based its selection process on the ... most outstanding in their medical specialties, in any area of medicine and in ...
    (Date:7/28/2015)... FL (PRWEB) , ... July 28, 2015 , ... ... to a number of publications, including Runner’s World Magazine, is plantar fasciitis ... this constant pain. , Designed by a professional athletic trainer, the Zensah ...
    Breaking Medicine News(10 mins):Health News:Brookstone Now Offers SmileCareClub Teeth Straightening System 2Health News:Brookstone Now Offers SmileCareClub Teeth Straightening System 3Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2